Spring Arbor Living Blog

As we age and our memory starts to fade, we all worry about our mental health and the potential for cognitive decline. But maintaining our mental health may not be any harder than going for a walk. A new, nine year study found that walking can keep dementia at bay. So put on your sneakers and go for a walk. Walking six miles a week protects the brain from shrinkage, which may slow the progress of cognitive decline.

Brain size shrinks late in adulthood which often is the start of dementia. Other studies suggest that physical activity protects against the deterioration of brain tissue, but no long-term studies have tested that theory. A study from the University of Pittsburgh wanted to do just that.

They asked 299 healthy, dementia-free men and women, average age 78, to keep track of the number of blocks they walked in a week.

After nine years, the researchers measured the brain size of the participants using high-resolution brain scans. The men and women who walked more had more gray matter. Those who walked approximately six to nine miles a week fared best, even after taking into account variables such as age, sex, body mass index and education. Walking more than 6-9 miles in a week didn't provide extra benefits.

Comments (0) | Trackbacks (0) | Permalink |

The link to healthy diets and brain health is well established. The link to diet and Alzheimer's disease is less clearly established, but new information on curcumin (found in turmeric) may prove to be helpful.

The brain is particularly vulnerable to oxidative damage due to its high rate of metabolism and long-lived neurons. Free radicals can cause oxidative damage to important cellular components such as DNA, or the cell membrane. Cells may function poorly or die if there is too much oxidative damage.

Antioxidants defend the cells from free radical damage. Many long term studies have demonstrated that those with higher antioxidants in their diets from fruits, vegetables and certain spices have slower rates of cognitive decline than those who ate less of these foods.

Curcumin has been studied recently because of the low rates of Alzheimer's disease in India. The Indian population consumes large amounts of curcumin through Tumeric and have a relatively low (4 times less) incidence of Alzheimer's disease compared to the U.S. population.

Curcumin is a member of the ginger family and is the main ingredient of turmeric, a spice used in curry and many Middle Eastern dishes. Curcumin is an antioxidant with nonsteroidal anti-inflammatory properties which prevents the damage caused by free radicals. The more antioxidants in the diet, the more the cells are protected.

The National Institutes of Health and other research organizations have been completing Alzheimer's clinical trials. Recently, curcumin has been in the forefront of much of this research. Curcumin's powerful anti-inflammatory and anti-oxidant properties suppress the buildup of beta-amyloid in brain tissue.

The National Institute of Neurological Disorders and Stroke (NINDS) studied mice and found that curcumin crosses the blood-brain barrier to bind with beta-amyloid peptides. These peptides are dangerous when they build up into plaques.

As Alzheimer's disease develops, neurons go through a process from a healthy state to some loss of molecular efficiency, to a loss of synaptic function, to loss of synapses, and, ultimately, to cell death. When curcumin was fed to aged mice, there was a reduction in amyloid levels and the overall amount of dangerous plaque.

More studies are needed to investigate the safety and tolerability of curcumin in the elderly population. Research is also needed in the areas of using curcumin to prevent Alzheimer's Disease as well as to lessen symptoms.

As clinical trials produce more information about the efficacy of curcumin, guidelines will be established for those at risk and for those affected.

Original article on CDApress.com by Seanne Safail, , Ph.D, RD

Comments (0) | Trackbacks (0) | Permalink |

Disease develops years before symptoms show.

New guidelines for diagnosing Alzheimer's disease set forth methods for identifying the disease before it progresses to full-blown dementia, and for the first time include lab and brain-imaging tests that can help identify Alzheimer's as the likely cause of a person's mental decline.

The guidelines, revised for the first time in 27 years, reflect a firm consensus among Alzheimer's researchers that the disease begins to attack the intricate structures of the brain 10 years or more before the disabling mental problems appear. Therefore, to be effective, drug or other therapies will have to begin work early in that process.

So far, though, there are no therapies that alter the course of Alzheimer's disease. And in a media briefing, authors of the new diagnosis guidelines emphasized that while testing for Alzheimer's pathology in the brain may one day be used to identify the disease at much earlier stages, today the tests are primarily a research tool. They are not ready for routine use in doctors' offices.

Delaying disability

Even so, doctors hope the new diagnostic criteria encourage people with worrisome memory problems to seek help. There's a lot patients and their families can do to minimize the impact of Alzheimer's, from structuring the patient's environment to optimizing medical care, activities, exercise and diet.

New tests outlined in the guidelines involve looking at the brain with imaging technologies and examining the fluid obtained by a spinal tap. The imaging studies can reveal so-called plaques made up of a protein called amyloid, a defining feature of Alzheimer's. They also can indicate characteristic patterns of shrinkage or reduced metabolic activity in the brain. The cerebrospinal fluid tests look for levels of amyloid as well as of another protein, tau, which makes up the twisted strands or "tangles" that, like plaques, are signature brain pathology in Alzheimer's.

Weaknesses of the tests

Research studies have demonstrated that all these tests can help identify Alzheimer's as the cause of a patient's dementia, and can help predict which patients with milder symptoms will go on to develop dementia. But the tests aren't conclusive in themselves. They aren't standardized so that a certain result means the same thing in every medical center. And there's no clear cutoff separating normal findings from those indicating a problem.

Original article by: Katharine Greider from AARP Bulletin

Comments (0) | Trackbacks (0) | Permalink |

Brain scans may help identify which individuals with a mild decline in their mental abilities will go on to develop Alzheimer's disease, according to a new study.
 
The research focused on patients with mild cognitive impairment, a condition in which people experience noticeable declines in their cognitive function, including memory and language problems. These changes are not severe enough to interfere with everyday activities, according to the Alzheimer's Association.
It is known that about 15 to 20 percent of such patients will go on to develop Alzheimer's, but researchers don't know which ones.

In the new study, which involved magnetic resonance imaging (MRI), researchers were able to identify a high-risk group – patients who had a 69 percent chance of developing Alzheimer's disease in the next year.

The study used the MRI scans to identify brain characteristics that put people at risk for Alzheimer's. The researchers determined some patients had just a 3 percent risk of developing Alzheimer's in the next year, which is about the same as for a healthy older person. Others had a 40 percent risk of developing the condition in the next year, or double the risk associated with a diagnosis of mild cognitive impairment, and still others were identified as part of the high-risk group, said study researcher Linda K. McEvoy, an assistant professor in the department of radiology at the University of California, San Diego School of Medicine.

A similar technique could be used one day by doctors to determine the Alzheimer's risk for patients with mild cognitive impairment. However, the patients in the study were not representative of the general population — they had been selected to exclude people who experienced other types of memory problems, such as those due to a stroke. A larger study would be needed before the results could be translated to the doctor's office.

Alzheimer's disease risk
The study looked at MRI scans of the brains of 203 healthy adults, 164 patients with Alzheimer's disease and 317 patients with mild cognitive impairment. Each patient had their brain scanned at the start of the study and again a year later.

The researchers first compared the brains of Alzheimer's disease patients with those of healthy people, looking for differences in the degree of  shrinkage, or atrophy, in particular areas of the brain. Once they developed a way to distinguish these two groups of people, "we could use the same equations on the mild cognitive impairment (MCI) subjects to determine their risk of developing Alzheimer's disease," McEvoy said.
 
When the researchers included information about how the brains had changed in the time between the two scans, they were able to identify the high-risk group.

Future applications
Information in this study will be critical once we have ways to prevent Alzheimer's disease, McEvoy said. "Currently there's no cure or prevention for Alzheimer's disease. But there's a lot of research going on right now into different potential therapies. If any of those therapies turn out to be useful, then this kind of information will be crucial — a doctor needs to know who's at higher risk in order to treat them".

 Original article by Rachael Rettner- MyHealthNewsDaily

Comments (0) | Trackbacks (0) | Permalink |

Alzheimer's disease symptoms result from physical changes in the brain. What causes these changes is still somewhat of a mystery, however researchers have a leading theory of how the Alzheimer's disease progresses.
 
In a healthy brain, certain chemical processes ensure the proper functioning of neurons. One is the processing of amyloid precursor protein (APP) that is attached to the outer membrane of nerve cells. Certain enzymes cut off a section of the protein; while another enzyme snips a second portion and releases APP from the cell’s membrane.

These APP fragments are then broken down and removed from the brain. Another process, which we won’t get into here, carries nutrients through the nerve cells to keep them functioning normally.
 
When the processes that keep a healthy brain functioning go awry, a different enzyme, cuts shorter APP fragments from the nerve cell membrane. These smaller pieces are more resistant to breakdown and tend to clump together in toxic clusters and eventually they collect into plaques that interfere with nerve cell functioning. Within neurons, the transport of nutrients is crippled and nerve cells are destroyed. Loose threads join together to form knotted strands inside neurons. These cause further neuron destruction.

In the early stages of Alzheimer’s, plaques and tangles form in brain areas responsible for learning, thinking, and planning -- in particular, the hippocampus. This is why forgetfulness, disorientation, and verbal repetition are often among the earliest signs of Alzheimer’s. As nerve cell destruction spreads more brain areas are affected, especially the cerebral cortex, responsible for language, reasoning, and judgment. Speaking skills become impaired and emotional outbursts grow more frequent.

When large areas of nerve cells die off in the advanced Alzheimer’s stage, brain sections atrophy and the whole brain shrinks to as much as three quarters of its original size. People with Alzheimer’s lose most of their ability to communicate, walk, and care for themselves.  

Comments (0) | Trackbacks (0) | Permalink |